<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876924</url>
  </required_header>
  <id_info>
    <org_study_id>ORF-01-001</org_study_id>
    <nct_id>NCT04876924</nct_id>
  </id_info>
  <brief_title>A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantero Therapeutics, a BridgeBio company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantero Therapeutics, a BridgeBio company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of BBP-711 in healthy&#xD;
      adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, two-part, randomized, double-blinded, placebo-controlled, ascending&#xD;
      dose study of BBP-711 in healthy male and female adult volunteers. The purpose of this study&#xD;
      is to evaluate the safety and tolerability of BBP-711 in healthy adult volunteers. Each&#xD;
      volunteer will participate in the study for about 20 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline to Day 20</time_frame>
    <description>Incidence of Adverse Events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments: Cmax</measure>
    <time_frame>Blood samples will be taken pre-dose up to Day 10 for SAD and pre-dose up to Day 20 for MAD</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments: Cmin</measure>
    <time_frame>Blood samples will be taken pre-dose up to Day 10 for SAD and pre-dose up to Day 20 for MAD</time_frame>
    <description>Minimum observed plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments: AUC</measure>
    <time_frame>Blood samples will be taken pre-dose up to Day 10 for SAD and pre-dose up to Day 20 for MAD</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to last measurable concentration (AUC(0-last)) computed using the linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Assessment: Baseline plasma glycolate</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline plasma glycolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Assessment: Percentage change from baseline plasma glycolate</measure>
    <time_frame>Blood samples will be taken pre-dose up to Day 10 for SAD and pre-dose up to Day 20 for MAD</time_frame>
    <description>Percentage change from baseline plasma glycolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Assessment: Baseline 24 Hour urinary glycolate:creatinine ratio</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline 24 Hour urinary glycolate:creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Assessment: Percentage change from baseline of 24 Hour urinary glycolate:creatinine ratio</measure>
    <time_frame>Urine samples will be taken pre-dose up to Day 3 for SAD and pre-dose up to Day 7 for MAD</time_frame>
    <description>Percentage change from baseline of 24 Hour urinary glycolate:creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BBP-711 for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of BBP-711 will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of matching placebo will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBP-711 for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of BBP-711 will be administered orally for multiple days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A dose of matching placebo will be administered orally for multiple days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBP-711 for SAD Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of BBP-711 will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD Food Effect</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of matching placebo will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBP-711</intervention_name>
    <description>BBP-711, oral suspension</description>
    <arm_group_label>BBP-711 for MAD</arm_group_label>
    <arm_group_label>BBP-711 for SAD</arm_group_label>
    <arm_group_label>BBP-711 for SAD Food Effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BBP-711</description>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_label>Placebo for SAD Food Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female who is 18 to 65 years old,&#xD;
&#xD;
          -  Weight &gt;50 kg and â‰¤110 kg at Screening&#xD;
&#xD;
          -  Body mass index (BMI) 20 to 32 kg/m2, inclusive, at Screening&#xD;
&#xD;
          -  In generally good health&#xD;
&#xD;
          -  Nonsmoker, or not using tobacco or nicotine-containing products for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any over-the-counter medications, including herbals or routine vitamins or&#xD;
             minerals, or other supplements, within 7 days before admission to the research center.&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  eGFR &lt;90 mL/minute&#xD;
&#xD;
          -  Abnormal ECG&#xD;
&#xD;
          -  Abnormal laboratory results&#xD;
&#xD;
          -  Positive test result for HIV, Hepatitis B, Hepatitis C, or COVID-19&#xD;
&#xD;
          -  History of substance dependency (alcohol or other drugs of abuse) in the last 2 years&#xD;
&#xD;
          -  Use of study drug in any clinical trial within 30 days of admission to the research&#xD;
             center, or in the active follow-up phase of another clinical trial involving study&#xD;
             drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zaira Bencomo</last_name>
    <phone>+1 602-437-0097</phone>
    <email>info@celerion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

